189 related articles for article (PubMed ID: 34256096)
1. Androgen receptor splice variant 7 functions independently of the full length receptor in prostate cancer cells.
Liang J; Wang L; Poluben L; Nouri M; Arai S; Xie L; Voznesensky OS; Cato L; Yuan X; Russo JW; Long HW; Brown M; Chen S; Balk SP
Cancer Lett; 2021 Oct; 519():172-184. PubMed ID: 34256096
[TBL] [Abstract][Full Text] [Related]
2. ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer.
Cato L; de Tribolet-Hardy J; Lee I; Rottenberg JT; Coleman I; Melchers D; Houtman R; Xiao T; Li W; Uo T; Sun S; Kuznik NC; Göppert B; Ozgun F; van Royen ME; Houtsmuller AB; Vadhi R; Rao PK; Li L; Balk SP; Den RB; Trock BJ; Karnes RJ; Jenkins RB; Klein EA; Davicioni E; Gruhl FJ; Long HW; Liu XS; Cato ACB; Lack NA; Nelson PS; Plymate SR; Groner AC; Brown M
Cancer Cell; 2019 Mar; 35(3):401-413.e6. PubMed ID: 30773341
[TBL] [Abstract][Full Text] [Related]
3. Androgen Receptor and Its Splicing Variant 7 Expression in Peripheral Blood Mononuclear Cells and in Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer.
Marín-Aguilera M; Jiménez N; Reig Ò; Montalbo R; Verma AK; Castellano G; Mengual L; Victoria I; Pereira MV; Milà-Guasch M; García-Recio S; Benítez-Ribas D; Cabezón R; González A; Juan M; Prat A; Mellado B
Cells; 2020 Jan; 9(1):. PubMed ID: 31947623
[TBL] [Abstract][Full Text] [Related]
4. A novel inhibitor of ARfl and ARv7 induces protein degradation to overcome enzalutamide resistance in advanced prostate cancer.
Li Y; Chu Y; Shi G; Wang X; Ye W; Shan C; Wang D; Zhang D; He W; Jiang J; Ma S; Han Y; Zhao Z; Du S; Chen Z; Li Z; Yang Y; Wang C; Xu X; Wu H
Acta Pharm Sin B; 2022 Nov; 12(11):4165-4179. PubMed ID: 36386477
[TBL] [Abstract][Full Text] [Related]
5. DNA binding alters ARv7 dimer interactions.
Özgün F; Kaya Z; Morova T; Geverts B; Abraham TE; Houtsmuller AB; van Royen ME; Lack NA
J Cell Sci; 2021 Jul; 134(14):. PubMed ID: 34318896
[TBL] [Abstract][Full Text] [Related]
6. Increased chromatin accessibility drives transition to androgen receptor splice variant dependence in castration-resistant prostate cancer.
Poluben L; Nouri M; Liang J; Varkaris A; Ersoy-Fazlioglu B; Voznesensky O; Lee II; Qiu X; Cato L; Seo JH; Freedman ML; Sowalsky AG; Lack NA; Corey E; Nelson PS; Brown M; Long HW; Balk SP; Russo JW
bioRxiv; 2024 Jan; ():. PubMed ID: 38260576
[TBL] [Abstract][Full Text] [Related]
7. Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth.
Yamamoto Y; Loriot Y; Beraldi E; Zhang F; Wyatt AW; Al Nakouzi N; Mo F; Zhou T; Kim Y; Monia BP; MacLeod AR; Fazli L; Wang Y; Collins CC; Zoubeidi A; Gleave M
Clin Cancer Res; 2015 Apr; 21(7):1675-87. PubMed ID: 25634993
[TBL] [Abstract][Full Text] [Related]
8. Androgen Receptor Upregulates Mucosa-Associated Lymphoid Tissue 1 to Induce NF-κB Activity via Androgen-Dependent and -Independent Pathways in Prostate Carcinoma Cells.
Chang KS; Chen ST; Sung HC; Hsu SY; Lin WY; Hou CP; Lin YH; Feng TH; Tsui KH; Juang HH
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047218
[TBL] [Abstract][Full Text] [Related]
9. Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer.
Moses MA; Kim YS; Rivera-Marquez GM; Oshima N; Watson MJ; Beebe KE; Wells C; Lee S; Zuehlke AD; Shao H; Bingman WE; Kumar V; Malhotra SV; Weigel NL; Gestwicki JE; Trepel JB; Neckers LM
Cancer Res; 2018 Jul; 78(14):4022-4035. PubMed ID: 29764864
[TBL] [Abstract][Full Text] [Related]
10. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival.
Hörnberg E; Ylitalo EB; Crnalic S; Antti H; Stattin P; Widmark A; Bergh A; Wikström P
PLoS One; 2011 Apr; 6(4):e19059. PubMed ID: 21552559
[TBL] [Abstract][Full Text] [Related]
11. Analysis of AR/ARV7 Expression in Isolated Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer (SAKK 08/14 IMPROVE Trial).
Hench IB; Cathomas R; Costa L; Fischer N; Gillessen S; Hench J; Hermanns T; Kremer E; Mingrone W; Mestre RP; Püschel H; Rothermundt C; Ruiz C; Tolnay M; Burg PV; Bubendorf L; Vlajnic T; Sakk SGFCCR
Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31374981
[TBL] [Abstract][Full Text] [Related]
12. Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival.
Peacock SO; Fahrenholtz CD; Burnstein KL
Mol Endocrinol; 2012 Dec; 26(12):1967-79. PubMed ID: 23023561
[TBL] [Abstract][Full Text] [Related]
13. Isoform-specific Activities of Androgen Receptor and its Splice Variants in Prostate Cancer Cells.
Nagandla H; Robertson MJ; Putluri V; Putluri N; Coarfa C; Weigel NL
Endocrinology; 2021 Mar; 162(3):. PubMed ID: 33300995
[TBL] [Abstract][Full Text] [Related]
14. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
Hu R; Lu C; Mostaghel EA; Yegnasubramanian S; Gurel M; Tannahill C; Edwards J; Isaacs WB; Nelson PS; Bluemn E; Plymate SR; Luo J
Cancer Res; 2012 Jul; 72(14):3457-62. PubMed ID: 22710436
[TBL] [Abstract][Full Text] [Related]
15. Proliferating cell nuclear antigen directly interacts with androgen receptor and enhances androgen receptor‑mediated signaling.
Lu S; Dong Z
Int J Oncol; 2021 Jul; 59(1):. PubMed ID: 33982774
[TBL] [Abstract][Full Text] [Related]
16. Incidence of androgen receptor and androgen receptor variant 7 coexpression in prostate cancer.
Vellky JE; Bauman TM; Ricke EA; Huang W; Ricke WA
Prostate; 2019 Dec; 79(16):1811-1822. PubMed ID: 31503366
[TBL] [Abstract][Full Text] [Related]
17. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.
Sun S; Sprenger CC; Vessella RL; Haugk K; Soriano K; Mostaghel EA; Page ST; Coleman IM; Nguyen HM; Sun H; Nelson PS; Plymate SR
J Clin Invest; 2010 Aug; 120(8):2715-30. PubMed ID: 20644256
[TBL] [Abstract][Full Text] [Related]
18. Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13.
Chen Z; Wu D; Thomas-Ahner JM; Lu C; Zhao P; Zhang Q; Geraghty C; Yan PS; Hankey W; Sunkel B; Cheng X; Antonarakis ES; Wang QE; Liu Z; Huang TH; Jin VX; Clinton SK; Luo J; Huang J; Wang Q
Proc Natl Acad Sci U S A; 2018 Jun; 115(26):6810-6815. PubMed ID: 29844167
[TBL] [Abstract][Full Text] [Related]
19. A Novel Small Molecule Targets Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer.
Yang Z; Wang D; Johnson JK; Pascal LE; Takubo K; Avula R; Chakka AB; Zhou J; Chen W; Zhong M; Song Q; Ding H; Wu Z; Chandran UR; Maskrey TS; Nelson JB; Wipf P; Wang Z
Mol Cancer Ther; 2020 Jan; 19(1):75-88. PubMed ID: 31554654
[TBL] [Abstract][Full Text] [Related]
20. T-LAK cell-originated protein kinase (TOPK) enhances androgen receptor splice variant (ARv7) and drives androgen-independent growth in prostate cancer.
Alhawas L; Amin KS; Salla B; Banerjee PP
Carcinogenesis; 2021 Apr; 42(3):423-435. PubMed ID: 33185682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
